GlassScriptPhysician profile
Deanna Crawford
NPI 1134870660
$10,028.77
in general payments reported to CMS, 2019-2025
29 companies · $2,688 in 2025
The $2,688 reported for 2025 was more than what 96% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,938 · 2023: $2,808 · 2024: $2,595 · 2025: $2,688.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,793 · Education: $298.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,792.85 |
| Education | $298.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,410.53 | 2022-2025 | |
| Amgen INC. | $1,917.16 | 2022-2025 | Enbrel, Otezla, Tavneos |
| Janssen Biotech, INC. | $1,173.49 | 2022-2025 | Tremfya, Simponi Aria, Remicade |
| Astrazeneca Pharmaceuticals LP | $1,013.46 | 2022-2025 | Saphnelo |
| Novartis Pharmaceuticals Corporation | $716.37 | 2022-2025 | |
| Ucb, INC. | $678.85 | 2022-2025 | Bimzelx, Cimzia |
| Lilly USA, LLC | $562.10 | 2022-2025 | Taltz, Olumiant |
| Glaxosmithkline, LLC. | $346.67 | 2022-2025 | Benlysta, Nucala |
| E.R. Squibb & Sons, L.L.C. | $322.57 | 2022-2025 | Orencia |
| Mallinckrodt Hospital Products INC. | $152.81 | 2022-2023 | Acthar |
| Horizon Therapeutics Plc | $136.92 | 2022-2023 | Krystexxa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $71.68 | 2023-2024 | Cyltezo |
| Aurinia Pharma U.S., INC. | $69.51 | 2022 | |
| Alexion Pharmaceuticals, INC. | $65.94 | 2023-2025 | Strensiq |
| Radius Health, INC. | $51.64 | 2023-2025 | Tymlos |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $50.00 | 2022 | |
| Ani Pharmaceuticals, INC. | $46.65 | 2024 | Purified Cortrophin Gel |
| Genentech USA, INC. | $34.65 | 2025 | Actemra |
| Genzyme Corporation | $26.03 | 2023 | |
| Invivyd INC | $24.81 | 2025 | Pemgarda |
| Pfizer INC. | $24.36 | 2025 | |
| Kyowa Kirin, INC. | $23.78 | 2025 | |
| Sobi, INC | $22.56 | 2024 | |
| Kiniksa Pharmaceuticals International, Plc | $21.09 | 2024 | Arcalyst |
| Bioventus LLC | $16.36 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.38 | 2022 | |
| Janssen Scientific Affairs, LLC | $14.10 | 2022 | |
| Janssen Pharmaceuticals, INC | $13.17 | 2025 | Tremfya |
| Organon LLC | $6.13 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deanna Crawford listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.